Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 17/20 | 0.44 |
| ▸ | SREBF1 | P36956 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16535031 | 0.95 | SREBF2 (0.45) | SREBF2SREBF1KDM4EMAPTATM | |
| Bromide SCHEMBL16535897 | 0.94 | SREBF2 (0.44) | SREBF2SREBF1KDM4EMAPTATM | |
| Hydrochloric Acid SCHEMBL16535162 | 0.94 | SREBF2 (0.44) | SREBF2SREBF1KDM4EMAPTATM | |
| SCHEMBL16535382 | 0.84 | SREBF2 (0.45) | SREBF2SREBF1MAPTATMALDH1A1 | |
| SCHEMBL16535422 | 0.84 | SREBF2 (0.44) | SREBF2SREBF1KDM4EMAPTATM | |
| SCHEMBL20197296 | 0.84 | SREBF2 (0.41) | SREBF2SREBF1KDM4EMAPTATM | |
| SCHEMBL16535946 | 0.83 | SREBF2 (0.46) | SREBF2SREBF1KDM4EMAPTATM | |
| SCHEMBL16535838 | 0.83 | SREBF2 (0.59) | SREBF2SREBF1KDM4EMAPTATM | |
| SCHEMBL16536558 | 0.83 | SREBF2 (0.47) | SREBF2SREBF1MAPTATMSMN1; SMN2 | |
| SCHEMBL22152727 | 0.82 | SREBF2 (0.43) | SREBF2SREBF1KDM4EMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | claimed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | claimed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | claimed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | claimed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2015031650-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | CHAKRAVARTY SARVAJIT (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | SREBF2 356/4885SREBF1 393/4885KDM4E 3356/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | SREBF2 9/4885SREBF1 8/4885KDM4E 2233/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | SREBF2 9/4885SREBF1 8/4885KDM4E 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.